Responding to FDA Form 483 Observations After a Drug CGMP Inspection
Regulatory checks are very essential in the aspect of making sure that pharmaceutical producers are adhering to the existing requirements of Good Manufacturing Practice (CGMP). In an inspection, U.S. Food and drug administration (FDA) might find conditions that may be against regulatory provisions. Such results are reported in the FDA Form. 483 – Inspectional Observations.
Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4)
The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products.
What is Quality by Design (QbD) in Regulatory Affairs?
Quality by Design (QbD) in Regulatory Affairs is a systematic, science-based approach to pharmaceutical development that focuses on building quality into a product from the earliest stages rather than testing it at the end.
What is a Pre-IND Meeting for US FDA?
A Pre-IND meeting for the US FDA is a formal meeting between a drug sponsor and the U.S. Food and Drug Administration (FDA) that takes place before submitting an Investigational New Drug (IND) application. The purpose of this meeting is to obtain regulatory guidance on the planned preclinical studies, clinical trial design, manufacturing information, and overall development strategy.
What is a Periodic Benefit-Risk Evaluation Report (PBRER)?
A Periodic Benefit-Risk Evaluation Report (PBRER) is a comprehensive pharmacovigilance document submitted by Marketing Authorization Holders (MAHs) to regulatory authorities to evaluate a medicine’s ongoing safety profile and its overall benefit-risk balance. The PBRER provides a structured analysis of new safety data collected during a defined reporting interval and determines whether the product’s benefits continue to outweigh its risks.